ACST Stock – (NASDAQ: ACST) is giving an update on the usage

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually giving an update on the usage of its “at the market” equity providing plan.

As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering program under which Acasti may issue as well as promote from time to time its common shares having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January 27, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares ended up being marketed at prevailing market rates averaging US$1.0747 a share. No securities were marketed throughout the facilities of the TSXV or, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with the services of theirs. As a result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March 5, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and can supply the Company with extra freedom in its ongoing review process to check out as well as evaluate strategic options.

About Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescribed drugs using OM3 fatty acids delivered both as totally free fatty acids and bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have substantial clinical proof of safety as well as efficacy for lowering triglycerides in individuals with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being formulated for patients with severe HTG.

Forward Looking Statements – ACST Stock

Statements in that press release that are not statements of historical or current fact constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking assertions involve known and unknown risks, uncertainties, along with other unknown components that may cause the actual results of Acasti to be materially different from historical results and even from any future results expressed or even implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks as well as uncertainties, readers are urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be uncertain and forward-looking. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the day of this press release. Forward-looking assertions in this press release include, but aren’t confined to, statements or information concerning Acasti’s strategy, future operations and the review of its of strategic alternatives.

The forward-looking statements found in this specific press release are expressly qualified in the entirety of theirs by this cautionary statement, the “Special Note Regarding Forward Looking Statements” section contained in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com as well as on the investor section of Acasti’s site at www.acastipharma.com. Most forward-looking statements in this press release are produced as of the particular date of this particular press release.

ACST Stock – Acasti doesn’t undertake to update some such forward-looking statements whether as a consequence of information which is brand new, future events or otherwise, except as called for by law. The forward-looking statements contained herein are also subject typically to assumptions and risks as well as uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, like Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use